Sugi Predict

Sugi Predict / Targets / NR2E3

NR2E3

Photoreceptor-specific nuclear receptor · Q9Y5X4 · NR2E3 on Sugi Atlas →

17,326 patent compounds predicted against NR2E3, 10,748 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1250494 SCHEMBL1250494 0.59 11/20
SCHEMBL1136390 SCHEMBL1136390 0.59 8/20
SCHEMBL1251122 SCHEMBL1251122 0.62 7/20
SCHEMBL1136397 SCHEMBL1136397 0.61 7/20
SCHEMBL1250718 SCHEMBL1250718 0.56 6/20
SCHEMBL1136351 SCHEMBL1136351 0.55 6/20
SCHEMBL1250181 SCHEMBL1250181 0.53 6/20
SCHEMBL1251970 SCHEMBL1251970 0.52 6/20
SCHEMBL1309845 SCHEMBL1309845 0.50 6/20
SCHEMBL1251157 SCHEMBL1251157 0.49 6/20
SCHEMBL1251055 SCHEMBL1251055 0.49 6/20
SCHEMBL1469018 SCHEMBL1469018 0.47 6/20
SCHEMBL1250990 SCHEMBL1250990 0.46 6/20
SCHEMBL1249034 SCHEMBL1249034 0.61 5/20
SCHEMBL1251528 SCHEMBL1251528 0.54 5/20
SCHEMBL1248653 SCHEMBL1248653 0.52 5/20
SCHEMBL1136458 SCHEMBL1136458 0.48 5/20
SCHEMBL1250342 SCHEMBL1250342 0.64 4/20
SCHEMBL1251455 SCHEMBL1251455 0.58 4/20
SCHEMBL1248959 SCHEMBL1248959 0.55 4/20

Clinical trials — most relevant to NR2E3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell. PHASE4UNKNOWN
Oral N-acetylcysteine for Retinitis Pigmentosa PHASE3ACTIVE_NOT_RECRUITING
A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy PHASE2/PHASE3UNKNOWN
A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa PHASE3ACTIVE_NOT_RECRUITING
Management of Retinitis Pigmentosa Via Combination of Wharton's Jelly-derived Mesenchymal Stem Cells and Magnovision PHASE3COMPLETED
Preoperative Bexarotene Treatment for Cushing's Disease PHASE1/PHASE2UNKNOWN
Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Subtenon Autologous Platelet-Rich Plasma in Inherited and Degenerative Retinal Diseases PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Intravitreal Adalimumab in Inherited and Degenerative Retinal Diseases PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis Pigmentosa PHASE1/PHASE2COMPLETED
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1) PHASE1/PHASE2RECRUITING
Clinical Gene Therapy Protocol for the Treatment of Retinal Dystrophy Caused by Defects in RPE65 PHASE1/PHASE2COMPLETED
Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye PHASE1COMPLETED
Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa PHASE1COMPLETED
Mechanisms of Inherited Retinal Dystrophies Using Whole Genome Sequencing and in Vitro and in Vivo Models nanCOMPLETED
Expanded Access Program for RP in Adults nanNO_LONGER_AVAILABLE
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases nanUNKNOWN
Natural History Study of Inherited Retinal Diseases nanRECRUITING
Clinical Characterization on PDE6A-related Retinitis Pigmentosa in Preparation to a Gene Therapy Trial nanCOMPLETED
Management of Retinitis Pigmentosa Via Electromagnetic Stimulation and Platelet Rich Plasma nanCOMPLETED
Hydroxychloroquine Dosing and Toxicity in Ophthalmology Clinics nanCOMPLETED
Steroid Treatment of Idiopathic Nephrotic Syndrome nanCOMPLETED
RETINA IMPLANT Alpha AMS in Blind Patients With Retinitis Pigmentosa nanWITHDRAWN
Biomarkers In Retinitis Pigmentosa (BIRP) nanCOMPLETED
RORC Genetic Polymorphism of Rheumatoid Arthritis nanCOMPLETED
Replacement of Vitamin D in Patients With Active Tuberculosis nanCOMPLETED
InsightRP2 Registry nanRECRUITING
Study IL- 35 Level and Fibronectin Type Ⅲ Domain Containing Protein 5 \ Irsin (FNDC5 rs3480) Gene Variations in Chronic Hepatitis B. nanUNKNOWN
EyeConic: Qualification for Cone-Optogenetics nanRECRUITING
Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a NR2E3 binder may also engage these)

ProteinNameSimilarity
Q9QXZ7 — 1.000 Q9QXZ7 →
Q9TTF0 — 1.000 Q9TTF0 →
RORC Nuclear receptor ROR-gamma 0.991 landscape →
P43136 — 0.991 P43136 →
Q5RAP4 — 0.990 Q5RAP4 →
NR1H3 Oxysterols receptor LXR-alpha 0.989 landscape →
Q5E9B6 — 0.989 Q5E9B6 →
NR2E1 Nuclear receptor subfamily 2 group E member 1 0.989 landscape →
P57753 — 0.988 P57753 →
Q9YGL3 — 0.988 Q9YGL3 →
Q62685 — 0.988 Q62685 →
P51450 — 0.987 P51450 →
Q9TU15 — 0.987 Q9TU15 →
Q62227 — 0.987 Q62227 →
Q9YH33 — 0.987 Q9YH33 →
Q9XSB5 — 0.987 Q9XSB5 →
NR4A1 Nuclear receptor subfamily 4immunitygroup A member 1 0.987 landscape →
NR1H2 Oxysterols receptor LXR-beta 0.987 landscape →
Q9W669 — 0.986 Q9W669 →
Q9IAL9 — 0.986 Q9IAL9 →
NR5A1 Steroidogenic factor 1 0.986 landscape →
P50242 — 0.986 P50242 →
O13012 — 0.986 O13012 →
Q5QJV7 — 0.986 Q5QJV7 →
Q9XSW2 — 0.986 Q9XSW2 →
P33242 — 0.986 P33242 →
P97947 — 0.986 P97947 →
P12813 — 0.986 P12813 →
P50569 — 0.986 P50569 →
Q9TTR7 — 0.985 Q9TTR7 →